General Information of Drug (ID: DMC0YOE)

Drug Name
AGN193109 Drug Info
Synonyms AGN 193109; AGN-93109
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
177238
CAS Number
CAS 171746-21-7
TTD Drug ID
DMC0YOE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [3]
Tamibarotene DM3G74J T-cell leukaemia 2A90 Phase 3 [4]
PMID27336223-Compound-10 DMYUP6G N. A. N. A. Patented [5]
PMID27336223-Compound-8 DM460D1 N. A. N. A. Patented [5]
PMID27336223-Compound-7 DM9QM6I N. A. N. A. Patented [5]
CD666 DMC8X9Y Discovery agent N.A. Investigative [6]
AC55649 DM4JNY9 Discovery agent N.A. Investigative [7]
BMS641 DMRT7G3 Discovery agent N.A. Investigative [8]
AC261066 DMSKE1I Discovery agent N.A. Investigative [7]
TTNPB DMSABD0 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [10]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [3]
Trifarotene DMOL793 Acne vulgaris ED80 Approved [11]
Tazarotene DM8SMD1 Acne vulgaris ED80 Approved [12]
Palovarotene DMAD2OZ Fibrodysplasia ossificans progressiva FB31.1 Approved [13]
PMID27336223-Compound-13 DMSZLYD N. A. N. A. Patented [5]
PMID27336223-Compound-12 DMT4P7K N. A. N. A. Patented [5]
PMID27336223-Compound-14 DMC41MA N. A. N. A. Patented [5]
PMID27336223-Compound-11 DMBN6KU N. A. N. A. Patented [5]
PMID27336223-Compound-15 DMIYCFE N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamibarotene DM3G74J T-cell leukaemia 2A90 Phase 3 [4]
IRX-5183 DMCED9U Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
SY-1425 DMH8UF0 Acute myeloid leukaemia 2A60 Phase 1 [15]
PMID27336223-Compound-4 DMJFSOM N. A. N. A. Patented [5]
PMID27336223-Compound-5 DM6E50A N. A. N. A. Patented [5]
LG100268 DM41RK2 Acquired immune deficiency syndrome 1C62.3 Discontinued in Phase 1 [16]
CD666 DMC8X9Y Discovery agent N.A. Investigative [6]
AGN193836 DMEB93D Discovery agent N.A. Investigative [17]
BMS614 DMZWNO9 Discovery agent N.A. Investigative [18]
Ro-40-0655 DM8PYAN Colorectal cancer 2B91.Z Investigative [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Antagonist [2]
Retinoic acid receptor beta (RARB) TTISP28 RARB_HUMAN Antagonist [2]
Retinoic acid receptor gamma (RARG) TT1Q3IE RARG_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2640).
2 Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
3 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
4 Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
5 Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
6 Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
7 Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9.
8 Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 2004 Sep;5(9):877-82.
9 9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6117-22.
10 Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
12 Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31.
13 Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12.
14 Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91.
17 Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.
18 Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92.
19 Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8.